A patient's response to immune checkpoint inhibitors (ICIs) is a complex quantitative trait,
and determined by multiple intrinsic and extrinsic factors. Three currently FDA-approved …

Immunotherapeutic interventions are showing effectiveness across a wide range of cancer
types, but only a subset of patients shows clinical response to therapy. Responsiveness to …

Owing to their tremendous diversity and plasticity, immune cells exert multifaceted functions
in tumor-bearing hosts, ranging from anti-tumor to pro-tumor activities. Tumor immune …

Abstract Anti-PD-1/PD-L1 monoclonal antibodies have substantially improved the overall
survival of a subset of patients across multiple solid tumour types, but other patients can …

adenosine monophosphate (AMP)-activated protein kinase (AMPK) is an evolutionarily
conserved serine/threonine kinase that was originally identified as the key player in …

Background Programmed death-ligand 1 (PD-L1) expression is the only FDA-approved
biomarker for immune checkpoint inhibitors (ICIs) in patients with lung adenocarcinoma, but …

Immunotherapies such as checkpoint-blocking antibodies and adoptive cell transfer are
emerging as treatments for a growing number of cancers. Despite clinical activity of …

KRAS-driven lung cancers frequently inactivate TP53 and/or STK11/LKB1, defining tumor
subclasses with emerging clinical relevance. Specifically, KRAS-LKB1 (KL)–mutant lung …

Inflammation, especially chronic inflammation, plays a pivotal role in tumorigenesis and
metastasis through various mechanisms and is now recognized as a hallmark of cancer and …

Immune checkpoint inhibitors against PD-1/PD-L1 yield improved survival rates of KRAS-
mutant NSCLC patients, who conferred a poor prognosis without effective targeted therapy …